120 patents
Utility
Double-stranded nucleic acid inhibitor molecules modified with Tm-increasing nucleotides
16 Jan 24
Provided herein are double-stranded nucleic acid inhibitor molecules having a sense strand with a stem loop structure and an antisense strand, where the stem portion of the stem loop structure contains one or more Tm-increasing nucleotides.
Weimin Wang, Naim Nazef, Bob Dale Brown
Filed: 11 Apr 19
Utility
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
16 Jan 24
This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 25 Jan 21
Utility
Compositions and Methods for Inhibiting Transmembrane Serine Protease 6 (TMPRSS6) Expression
4 Jan 24
Oligonucleotides are provided herein that inhibit TMPRSS6 expression.
Anna Linda Blois, Christina Marie Priest, Jihye Park, Henryk Dudek
Filed: 23 Jun 23
Utility
Compositions and Methods for Inhibiting Snca Expression
28 Dec 23
Oligonucleotides (e.g., RNAi oligonucleotides) are provided herein that inhibit SNCA gene expression, including oligonucleotides conjugated to a targeting ligand (e.g., GalNAC moiety or lipid moiety).
Bob Dale BROWN, Henryk T. DUDEK, Seongmoon CHEONG, Shiyu WANG, Travis GRIM, Matthew Guese COSTALES, Maire JUNG
Filed: 12 May 23
Utility
Chemical Modifications for Inhibiting Expression of ALDH2
28 Dec 23
This disclosure relates to chemically modified oligonucleotides, compositions, and methods useful for reducing ALDH2 expression, to treat alcoholism.
Bob Dale BROWN, Henryk T. DUDEK, Utsav SAXENA
Filed: 12 Nov 21
Utility
Reducing Beta-catenin Expression to Potentiate Immunotherapy
7 Dec 23
Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy.
Shanthi GANESH, Marc ABRAMS
Filed: 28 Dec 22
Utility
Compositions and Methods for Modulating Scap Activity
23 Nov 23
Oligonucleotides and compositions including the same are disclosed that modulate (e.g., inhibit, limit or reduce) sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP) activity.
Bob Dale BROWN, Henryk T. DUDEK, Seongmoon CHEONG, Nicole Alexis SPIEGELMAN
Filed: 14 Apr 23
Utility
Compositions and Methods for Inhibiting GYS2 Expression
16 Nov 23
This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes.
Bob D. Brown, Natalie PURSELL, Henryk T. DUDEK, Cheng LAI
Filed: 18 Jan 23
Utility
Reducing beta-catenin and IDO expression to potentiate immunotherapy
14 Nov 23
Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy.
Shanthi Ganesh
Filed: 3 Jan 19
Utility
Oligonucleotide Treatment of Hepatitis B Patients
9 Nov 23
The present invention provides oligonucleotides for use in the treatment of hepatitis B or hepatitis B virus infection in a human patient.
Søren OTTOSEN, Henrik MUELLER, Hardean ACHNECK, Douglas M. FAMBROUGH, Bob Dale BROWN
Filed: 3 Feb 23
Utility
Compositions and Methods for the Treatment of Metabolic Syndrome
26 Oct 23
Disclosed are methods for treating, preventing and alleviating obesity, fatty liver syndrome, diabetes, liver fibrosis, NASH or other more metabolic syndrome conditions or complications comprising administering an effective amount of oligonucleotides designed to prevent, limit or modulate the expression of mRNA molecules, preferably ACC and/or DGAT2.
Marc ABRAMS, Elisabeth WONDIMU, Soumik BASURAY
Filed: 4 Aug 21
Utility
Compositions and Methods for Inhibiting Mitochondria Amidoxime Reducing Component 1 (MARC1) Expression
26 Oct 23
Oligonucleotides are provided herein that inhibit MARC1 expression.
Henryk Dudek, Wen Han, Natalie Wayne Pursell, Chengjung Lai, William Geoffrey Haynes, Zhihao Ding
Filed: 14 Apr 23
Utility
Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNA
3 Oct 23
This invention relates to compounds, compositions, and methods useful for reducing C5 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 17 Dec 20
Utility
Systemic Delivery of Oligonucleotides
7 Sep 23
The disclosure provides oligonucleotide-ligand conjugates to facilitate the systemic delivery of oligonucleotides designed to prevent, limit or modulate the expression of mRNA molecules.
Weimin WANG, Bob Dale BROWN, Hongchuan YU, Xiaochuan CAI, Marc ABRAMS
Filed: 21 Jul 21
Utility
Compositions and Methods for Modulating APOC3 Expression
31 Aug 23
Oligonucleotides and compositions including the same are disclosed for inhibiting or reducing apolipoprotein C-III (APOC3) gene expression.
Bob Dale BROWN, Henryk DUDEK, Utsav SAXENA, Wen HAN
Filed: 1 Dec 22
Utility
PCSK9 Targeting Oligonucleotides for Treating Hypercholesterolemia and Related Conditions
10 Aug 23
This disclosure relates to oligonucleotides, compositions and methods useful for reducing PCSK9 expression, particularly in hepatocytes.
Henryk T. DUDEK, Jihye Park
Filed: 30 Nov 22
Utility
Compositions and Methods for Inhibiting Nuclear Receptor Subfamily 1 Group H Member 3 (NR1H3) Expression
13 Jul 23
Oligonucleotides are provided herein that inhibit NR1H3 expression.
Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen
Filed: 6 Jan 23
Utility
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
11 Jul 23
This invention relates to compounds, compositions, and methods useful for reducing transthyretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 1 Jul 21
Utility
Compositions and methods for inhibiting ALDH2 expression
30 May 23
This disclosure relates to oligonucleotides, compositions and methods useful for reducing ALDH2 expression, particularly in hepatocytes.
Utsav Saxena
Filed: 15 Jan 19
Utility
Methods and compositions for inhibiting expression of LDHA
30 May 23
This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
Bob D. Brown, Henryk T. Dudek, Utsav Saxena, Natalie Pursell, Cheng Lai, Weimin Wang, Rachel Storr, Naim Nazef, Boyoung Kim
Filed: 16 Sep 20